Program
Anti-nectin-4 Antibody-drug Conjugate MK-3120
Also written as “MK-3120” and “SKB410 for injection”.
Its studies are mostly in Urinary Bladder Neoplasms · Neoplasms · Carcinoma, Transitional Cell, led by 2 companies.
Drug pageAnti-nectin-4 Antibody-drug Conjugate MK-3120: every studyAll 5 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Merckits history only | 44 open or running | phase 2since Sep 28, 2022 | Sep 28, 2022 | Jul 30, 2027phase 2 · NCT07222488 |
| Sichuan Kelun Pharmaceuticalits history only | 10 open or running | phase 1since May 16, 2023 | May 16, 2023 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 28, 2022First study: phase 2 study in Carcinoma, Transitional CellNew to MerckMerck · NCT05562830 · 48 enrolled · United States, Australia, Canada and more
- May 16, 2023Sichuan Kelun Pharmaceutical’s first study: phase 1 study in Advanced Solid TumorsNew to Sichuan Kelun PharmaceuticalSichuan Kelun Pharmaceutical · NCT05906537 · 38 enrolled · China
- Feb 7, 2025Phase 2 study in NeoplasmsMerck · NCT06818643 · 270 planned · United States, Chile, China and more
- Oct 27, 2025Phase 2 study in Urinary Bladder NeoplasmsMerck · NCT07222488 · 45 planned · United States, Austria, Belgium and more
- Nov 14, 2025Phase 2 study in Urinary Bladder NeoplasmsMerck · NCT07232602 · 55 planned · United States, Chile, France and more
- Oct 6, 2026Primary completion moved from 2028-10-25 to 2031-03-07Date moved laterphase 2 · +28 months · NCT06818643
Ahead
- Jul 30, 2027Primary completion: phase 2 study in Urinary Bladder NeoplasmsMerck · NCT07222488
- Feb 8, 2028Primary completion: phase 2 study in NeoplasmsMerck · NCT06818643
- Feb 26, 2029Primary completion: phase 2 study in Carcinoma, Transitional CellMerck · NCT05562830
- Jul 8, 2031Primary completion: phase 2 study in Urinary Bladder NeoplasmsMerck · NCT07232602
TargetBeta
“An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against the cell surface adhesion molecule and tumor-associated antigen (TAA) nectin-4 (PVRL4) ”NCIt, by rule
Other programs on NECTIN4
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| enfortumab vedotinrule | Astellas Pharma | phase 4 | 20 |
| notiretatug rezetecan | Jiangsu HengRui Medicine | phase 3 | 14 |
| bulumtatug fuvedotinrule | Mabwell (Shanghai) Bioscience | phase 3 | 13 |
| Sutantatug Envedotinrule | CSPC Pharmaceutical Group | phase 3 | 6 |
| zelenectide pevedotinrule | bicycletx-limited | phase 2 | 5 |
| Anti-nectin-4/Anti-TROP2 Bispecific Antibody-drug Conjugate AVZO-103rule | avenzo-therapeutics-inc | phase 2 | 1 |
| Anti-nectin-4 Antibody-drug Conjugate IPH4502rule | innate-pharma | phase 1 | 1 |
| Anti-nectin-4/CD28 Bispecific Antibody RNDO-564rule | rondo-therapeutics | phase 1 | 1 |
| CT-202rule | context-therapeutics-inc | phase 1 | 1 |
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07232602Urinary Bladder Neoplasms · United States, Chile, France and more | 2 | Recruiting | Merck | Jul 8, 2031 | 55 |
| NCT07222488Urinary Bladder Neoplasms · United States, Austria, Belgium and more | 2 | Recruiting | Merck | Jul 30, 2027 | 45 |
| NCT06818643Neoplasms · United States, Chile, China and more | 2 | Recruiting | Merck | Feb 8, 2028 | 270 |
| NCT05906537Advanced Solid Tumors · China | 1 | Completed | Sichuan Kelun Pharmaceutical | Mar 31, 2026 | 38 |
| NCT05562830Carcinoma, Transitional Cell · United States, Australia, Canada and more | 2 | Active, not recruiting | Merck | Feb 26, 2029 | 48 |
How it is read
Names in the registry
- “MK-3120”, 4 entries
- “SKB410 for injection”, 1 entry
Conditions, from the studies’ own filings
- Urinary Bladder Neoplasms, 2 studies
- Neoplasms, 1 study
- Carcinoma, Transitional Cell, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.